Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Renato Lopes MD, MHS, PhD, FACC

Renato D. Lopes MD, MHS, PhD, FACC

Professor of Medicine, Division of Cardiology, Duke University Health System, Durham, North Carolina

Dr. Lopes is a cardiologist and professor in the Department of Medicine of the Division of Cardiology at Duke University Medical Center, in Durham, North Carolina. He is director of clinical events classification and the co-director of the Integrated Clinical Events—Safety Surveillance Group at the Duke Clinical Research Institute.

Dr. Lopes has an interest in novel antithrombotic therapies for the management of patients with atrial fibrillation and acute coronary syndromes as well as in the discovery of new biomarkers in cardiology. He has led several national and international clinical trials and registries. He has also participated in more than 130 clinical events committees (CECs) for many important clinical trials, serving as CEC chair and/or principal investigator for many of them.

Dr. Lopes has delivered more than 600 international lectures around the world, authored or co-authored more than 730 peer-reviewed articles, 30 book sections as well as 8 books, and has participated in several international guidelines.

In 2023, Dr. Lopes has been recognized as the top 1% most cited researcher in the field of clinical medicine over the past decade according to Clarivate and based on citations on web of science.

Disclosures

RDL has received research grants or contracts from Amgen, Bristol-Myers Squibb, GlaxoSmithKline, Medtronic, Pfizer, Sanofi-Aventis; funding for educational activities or lectures from Pfizer, Bristol-Myers Squibb, Daiichi Sankyo, and Novo Nordisk; and funding for consulting or other services from Bayer, Boehringer Ingelheim, Pfizer, Bristol-Myers Squibb, Novo Nordisk.